Botulinum toxin type A: History and current cosmetic use in the upper face

Disease-a-Month

Volumn 48, Issue 5, 2002, Pages 299-322

  Carruthers, Alastair ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ACETYLCHOLINE RELEASE; AGING; CLOSTRIDIUM BOTULINUM; DRUG MECHANISM; DYSTONIA; ELECTROMYOGRAPHY; ESTHETIC SURGERY; FACE MUSCLE; HUMAN; IMMUNOGENICITY; INJECTION; MUSCLE HYPERTONIA; REVIEW; TECHNIQUE;

EID: 0036558886     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1053/mda.2001.25138     Document Type: Article

References (85)

1. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion
2. Botulinum toxin type A (BTX-A) for migraine: An open label assessment
3. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections
4. Botulinum toxin type A as a migraine preventive treatment
5. Use of botulinum toxin in chronic daily headaches associated with migraine
6. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin
7. Notes on Bacillus botulinus
8. Preparation and characterization of botulinum toxin type A for human treatment
9. Studies on botulinus toxin. 3. Acid precipitation of botulinus toxin
10. Historical perspective
11. Botulinum toxin: The story of its development for the treatment of human disease
12. Pharmacologic weakening of extraocular muscles
13. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery
14. Assessment: The clinical usefulness of botulinum toxin-A in treating neurologic disorders
15. Assessment: Training guidelines for the treatment of neurologic disorders
16. Ophthalmic procedures assessment. Botulinum toxin therapy of eye muscle disorders
17. Statement: Botulinum A toxin for ocular muscle disorders
18. Position statement on the clinical usefulness of botulinum toxin in the treatment of spasmodic dysphonia
19. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Statement, November 12, 14, 1990
20. Focal hyperhidrosis: Effective treatment with intracutaneous botulinum toxin
21. Palmar and axillary hyperhidrosis treated with botulinum toxin: One-year clinical follow-up
22. A comparison of injection of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure
23. Review article: The use of botulinum toxin in the alimentary tract
24. Botulinum toxin injected in the gastric wall reduces body weight and food intake in rats
25. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm
26. Botulinum toxin A and mechanical low back pain
27. A common subunit structure in Clostridium botulinum type A, B and E toxins
28. Pharmacology of botulinum toxin
29. Clostridium botulinum toxins: Nature and preparation for clinical use
30. Proteolysis of SNAP-25 by types E and A botulinum neurotoxins
31. Tetanus and botulinum-B neurotoxins block transmitter release by proteolytic cleavage of synaptobrevin
32. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
33. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia
34. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia
35. Botulinum A toxin for the treatment of adult-onset spasmodic torticollis
36. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial
37. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm
38. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox® in the treatment of cervical dystonia
39. Development of resistance to botulinum toxin type A in patients with torticollis
40. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: Frequency and significance
41. BOTOX (botulinum toxin type A) purified neurotoxin complex prepared from the new bulk toxin retains the same preclinical efficacy as the original but with reduced immunogenicity
42. An interim analysis of the clinical status of patients receiving current BOTOX® (lot 2024 or subsequent lots) for the treatment of cervical dystonia (CD)
43. Treatment of glabellar frown lines with C. botulinum-A exotoxin
44. Botulinum A toxin for (expressionistic) ptosis overcorrection after frontalis sling
45. Botulinum toxin for the treatment of hyperfunctional lines of the face
46. The management of hyperfunctional facial lines with botulinum toxin
47. Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, vehicle-controlled study
48. Local injection into mimetic muscles of botulinum toxin A for the treatment of facial lines
49. Chemical brow lift
50. Treatment of facial synkinesis and facial asymmetry with botulinum toxin type A following facial nerve palsy
51. Botulinum A exotoxin for glabellar folds: A double-blind, vehicle controlled study with an electromyographic injection technique
52. Cosmetic denervation of the muscles of facial expression with botulinum toxin. A dose-response study
53. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injection
54. Quantifying how location and dose of botulinum toxin injection affect muscle paralysis
55. Cosmetic uses of botulinum A exotoxin
56. Dilution and storage of botulinum toxin
57. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection
58. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans
59. Intraoperative injection of botulinum toxin A into orbicularis oculi muscle for the treatment of crow's feet
60. Botulinum toxin: The Newport Beach Experience
61. Botulinum toxin for the correction of hyperkinetic facial lines
62. Botulinum toxin type A for facial rejuvenation: United States and United Kingdom perspectives
63. La toxine botulique dans le treatment de rides fronto-glabellaires et de la region orbitaire
64. Toxine botulique et rides faciales: Une nouvelle procedure d'injection botulinum toxin and facial wrinkles. A new injection procedure
65. Reconstituted botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use
66. Botulinum A toxin for glabellar wrinkles: Dose and response
67. Botulinum toxin in the treatment of facial expression wrinkles (ITA)
68. Innervation zone of orbicularis oculi muscle and implications for botulinum A toxin therapy
69. Cosmetic upper-facial rejuvenation with botulinum
70. Cosmetic use of botulinum toxin
71. Raising eyebrows with botulinum toxin
72. Temporal brow lift using botulinum toxin A
73. Brow lift with botulinum toxin
74. Bells palsy, management and sequelae using EMG rehabilitation, botulinum toxin and surgery
75. Botulinum toxin: A treatment for facial asymmetry caused by facial nerve paralysis
76. Botulinum toxin A injection in patients with facial nerve palsy
77. The adjunctive usage of botulinum toxin
78. Botulinum toxin can eradicate rhytides, improve overall results
79. Combining botulinum toxin injection and laser for facial rhytides
80. 2 laser resurfacing
81. The power of combined therapies: Botox and ablative facial laser resurfacing
82. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates